Cellectis (CLLS) Stock Overview
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CLLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cellectis S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.27 |
| 52 Week High | €5.48 |
| 52 Week Low | €1.10 |
| Beta | 2.98 |
| 1 Month Change | 5.17% |
| 3 Month Change | 7.29% |
| 1 Year Change | 182.78% |
| 3 Year Change | 40.00% |
| 5 Year Change | -86.50% |
| Change since IPO | -88.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.7% | -1.4% | 0.2% |
| 1Y | 182.8% | 27.9% | 16.9% |
Return vs Industry: CLLS exceeded the US Biotechs industry which returned 28.4% over the past year.
Return vs Market: CLLS exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| CLLS volatility | |
|---|---|
| CLLS Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLLS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLLS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 219 | Andre Choulika | www.cellectis.com |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Cellectis S.A. Fundamentals Summary
| CLLS fundamental statistics | |
|---|---|
| Market cap | US$298.13m |
| Earnings (TTM) | -US$35.35m |
| Revenue (TTM) | US$82.55m |
Is CLLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLLS income statement (TTM) | |
|---|---|
| Revenue | US$82.55m |
| Cost of Revenue | US$0 |
| Gross Profit | US$82.55m |
| Other Expenses | US$117.90m |
| Earnings | -US$35.35m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 100.00% |
| Net Profit Margin | -42.83% |
| Debt/Equity Ratio | 51.0% |
How did CLLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/15 03:37 |
| End of Day Share Price | 2026/01/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellectis S.A. is covered by 21 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Madhu Kumar | Baird |
| Huidong Wang | Barclays |